Impella支持患者的抗凝优化:专家共识解读
针对Impella经皮机械循环支持患者的抗凝管理复杂且各中心不一致的问题,专家委员会汇总现有证据,形成42条共识推荐,涵盖净化液管理、静脉抗凝、监测、肝素诱导的血小板减少症(HIT)的评估与管理,以及联合机械循环支持期间的抗凝管理。
要点
- 肝素化含葡萄糖净化液对装置最佳功能至关重要,碳酸氢盐净化液可作特定情况替代。
- 静脉肝素抗凝常有必要,但支持最佳监测项目和目标范围的证据普遍缺乏。
- Impella患者可能出现HIT,在该情境下评估和治疗更为困难。
核心结论
- 专家委员会基于现有证据形成42条共识推荐,以优化Impella支持患者的抗凝管理。
研究设计与样本
- 专家委员会汇总所有评估Impella支持患者抗凝的现有证据,形成共识推荐。
主要发现
- 共识推荐涉及净化液管理、静脉抗凝、监测、HIT的评估与管理及联合MCS支持期间的管理。
- 肝素化含葡萄糖净化液对装置最佳功能至关重要,碳酸氢盐净化液可在特定情况下替代。
- 静脉肝素抗凝常有必要,但支持最佳监测项目和目标范围的证据普遍缺乏。
- Impella患者可能发生HIT,在该情境下评估和治疗更困难。
- Impella联合ECMO或用于双心室支持带来额外抗凝挑战。
关键数值与推荐
- 共识共形成42条推荐,涵盖净化液管理、静脉抗凝、监测、HIT及联合MCS支持。
- 推荐使用肝素化含葡萄糖净化液以优化装置功能,碳酸氢盐净化液可作为特定情况下的替代。
- 静脉肝素抗凝常有必要,但最佳监测项目和目标范围缺乏证据支持。
临床怎么用
- 临床应优先使用肝素化含葡萄糖净化液,特定情况下可考虑碳酸氢盐净化液。
- 静脉肝素抗凝常需使用,但监测项目和目标范围需结合共识推荐及个体情况。
- 对Impella患者应评估HIT,并注意联合ECMO或双心室支持时的额外抗凝挑战。
局限性
- 支持最佳监测项目和目标范围的证据普遍缺乏。
- 各中心抗凝实践不一致,可能增加并发症风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anticoagulation of patients treated with the Impella percutaneous mechanical circulatory support (MCS) devices is complex and lacks consistency across centers, potentially increasing the risk of complications. In order to optimize safety and efficacy, an expert committee synthesized all available evidence evaluating anticoagulation for patients receiving Impella support in order to provide consensus recommendations for the management of anticoagulation with these devices. The evidence synthesis led to the creation of 42 recommendations to improve anticoagulation management related to the use of the Impella devices. Recommendations address purge solution management, intravenous anticoagulation, monitoring, evaluation and management of heparin-induced thrombocytopenia (HIT), and management during combination MCS support. The use of a heparinized, dextrose-containing purge solution is critical for optimal device function, and a bicarbonate-based purge solution may be an alternative in certain situations. Likewise, intravenous (ie, systemic) anticoagulation with heparin is often necessary, although evidence supporting the optimal assay and target range for monitoring the level of anticoagulation is generally lacking. Patients treated with an Impella MCS device may develop HIT, which is more difficult to evaluate and treat in this setting. Lastly, the use of Impella with extracorporeal membrane oxygenation or for biventricular support creates additional anticoagulation challenges.
引用
- Beavers CJ, DiDomenico RJ, Dunn SP, et al. Optimizing anticoagulation for patients receiving Impella support. Pharmacotherapy. 2021. PMID: 34597429. doi:10.1002/phar.2629
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。